<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317940</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-10-00273</org_study_id>
    <secondary_id>LLS 6249-11</secondary_id>
    <nct_id>NCT01317940</nct_id>
  </id_info>
  <brief_title>Nutrition and Body Composition in Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Nutrition and Body Composition in Acute Lymphoblastic Leukemia (Environment and Microenvironment in ALL #2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many adolescents with acute lymphoblastic leukemia (ALL) have been found to have low bone
      density by the end of treatment. This can lead to long-term suffering in survivors due to
      poor bone health. Vitamin D is known to be associated with bone health and previous research
      has established that Vitamin D insufficiency is very common at diagnosis of ALL and worsens
      over the course of treatment. Researchers have also learned that a relationship exists
      between both Vitamin D and fat tissue and ALL and fat tissue.

      In adolescents being treated for ALL as well as in early survivors, this randomized study
      will therefore examine the effect of Vitamin D and calcium supplementation on correcting
      Vitamin D insufficiency and on improving bone density in the context of changes in body
      composition and body fat. Bone density will be measured by a radiology exam called qCT
      (quantitative computed tomography) while body composition and body fat will be measured by a
      different radiology exam called a DXA (dual energy x-ray absorptiometry scan) . The study
      will also examine in depth the relationship between these three elements - Vitamin D
      insufficiency, obesity, and ALL - and their impact on bone density.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Vitamin D Level (Group A)</measure>
    <time_frame>+6 months</time_frame>
    <description>Change in Vitamin D levels from baseline to study end (Group A: Consolidation through end of Delayed Intensification)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density by Quantitative Computed Tomography (QCT) at Study End (Group A)</measure>
    <time_frame>+6 months</time_frame>
    <description>Bone mineral density (vBMD) at end of study period (Group A: end of Delayed Intensification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vitamin D Level (Group B)</measure>
    <time_frame>+6 months</time_frame>
    <description>Change in serum vitamin D level was assessed in survivors at baseline and after 6 months of supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density by QCT in Survivors at Study End (Group B)</measure>
    <time_frame>+6 months</time_frame>
    <description>Bone mineral density (vBMD) at end of study period (Group B: after 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Obesity and Vitamin D Insufficiency in Adolescents With Newly Diagnosed ALL and in Their Siblings</measure>
    <time_frame>1 timepoint</time_frame>
    <description>Insufficiency defined as 25(OH)D &lt; 30 ng/ml</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Precursor Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Group A (Newly Diagnosed Subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Group A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Early Survivors)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation Only - Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Siblings of Group A)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D and Calcium Citrate</intervention_name>
    <description>Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)
Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months</description>
    <arm_group_label>Group A (Newly Diagnosed Subjects)</arm_group_label>
    <arm_group_label>Group B (Early Survivors)</arm_group_label>
    <other_name>1,25-Dihydroxycholecalciferol</other_name>
    <other_name>Calcitriol</other_name>
    <other_name>Rocaltrol (Roche)</other_name>
    <other_name>Calcium carbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        GROUP A: Patients with newly diagnosed ALL

          -  Are greater than or equal to 10 years of age and less than or equal to 21 years of age
             at diagnosis of ALL

          -  Have a new diagnosis of untreated ALL classified as &quot;high risk&quot; per NCI criteria (due
             to being greater than 10 years of age)

          -  Are beginning treatment with a Children's Cancer Group/Children's Oncology Group &quot;high
             risk&quot; protocol with a 4-drug induction including steroids

          -  Are not pregnant

        GROUP B: Early survivors of ALL

          -  Were treated for ALL and remain in first CR1 (complete remission)

          -  Were equal to or greater than 10 years of age and less than or equal to 21 years of
             age at diagnosis of ALL

          -  Have completed treatment on or as per a Children's Cancer Group/Children's Oncology
             Group &quot;high risk&quot; protocol between 12 and 48 months prior to enrollment in this study
             (consisting of a plan for a 4-drug induction including steroids in Induction, Delayed
             Intensification, and steroid pulses in Maintenance. Steroids are allowed to have been
             discontinued due to toxicity).

          -  Are not pregnant

        GROUP C: Siblings of Group A

          -  Are either a full-sibling or a half-sibling of a patient in Group A

          -  Are living at the same residence as the sibling/half-sibling from Group A

          -  Are greater than or equal to 10 years of age and less than or equal to 21 years of age
             at the time of study entry, and within 3 years of the age diagnosis of ALL in the
             sibling/half-sibling from Group A

          -  Are on the same Vitamin D supplementation regimen (if any) as the sibling from Group A
             at the time of his or her diagnosis

        Exclusion Criteria (All Groups):

          -  Have a diagnosis of Down syndrome (Trisomy 21) or any genetic disease associated with
             abnormal bone development

          -  Are undergoing treatment with other medicines that affect bones including chronic use
             of of steroids, bisphosphonate therapy, or Vitamin D at average dose greater than 400
             international units (IU)/day

          -  Have an underlying diseases altering body structure (i.e. missing a limb, severe
             dysmorphism) or severely affecting mobility (i.e. total or hemiparesis)

          -  Have a history of chemotherapy or radiation for other cancers

          -  Cannot complete the radiology exams/radiology exams uninterpretable (i.e. people with
             a hip replacement or prosthesis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etan Orgel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Mittelman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ods.od.nih.gov/factsheets/vitamind/</url>
    <description>NIH Vitamin D Fact Sheet</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <results_first_submitted>August 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2020</results_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Etan Orgel</investigator_full_name>
    <investigator_title>Clinical Fellow</investigator_title>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Bone Density</keyword>
  <keyword>Body Fat</keyword>
  <keyword>Obesity</keyword>
  <keyword>Adipose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Group A: 2 participants enrolled but did not reach time of randomization (1 induction death, 1 severe toxicity/change in treatment plan) Group B: 2 subjects enrolled but did not reach time of randomization or undergo any study procedures (2 lost to follow-up)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>On-Therapy Intervention (Group A)</title>
          <description>Subjects randomized following Induction to receive education plus:
Vitamin D and Calcium Citrate: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months) Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day through study period (total treatment period approximately 6-7 months)P</description>
        </group>
        <group group_id="P2">
          <title>On Therapy Standard of Care (Group A)</title>
          <description>Subjects randomized following Induction to receive standard of care with education alone OR subjects ineligible for open-label randomization and followed as &quot;natural history&quot; cohort.</description>
        </group>
        <group group_id="P3">
          <title>On-Therapy &quot;Natural History&quot; (Group A)</title>
          <description>Patients enrolled prior to open-label randomization and those not eligible for randomization at end of induction</description>
        </group>
        <group group_id="P4">
          <title>Survivorship Intervention (Group B)</title>
          <description>Subjects randomized to receive education plus directly-observed therapy with open-label Vitamin D and chewable calcium</description>
        </group>
        <group group_id="P5">
          <title>Survivorship Standard of Care (Group B)</title>
          <description>Survivors randomized to receive standard of care with education alone OR subjects ineligible for open-label Vitamin D+ Calcium randomization and continued with follow-up only.</description>
        </group>
        <group group_id="P6">
          <title>Siblings of Survivors (Group C)</title>
          <description>Healthy siblings of survivors of pediatric acute lymphoblastic leukemia (ALL) for one-time assessment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in therapy plan</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>On Therapy Intervention (Group A)</title>
          <description>Subjects randomized following Induction to receive education plus:
Vitamin D and Calcium Citrate: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months) Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day through study period (total treatment period approximately 6-7 months)P</description>
        </group>
        <group group_id="B2">
          <title>On Therapy Standard of Care (Group A)</title>
          <description>Subjects randomized following Induction to receive standard of care with education alone</description>
        </group>
        <group group_id="B3">
          <title>On Therapy &quot;Natural History&quot; (Group A)</title>
          <description>Subjects surviving to end of Induction but ineligible for randomization for any reason</description>
        </group>
        <group group_id="B4">
          <title>Survivorship Intervention (Group B)</title>
          <description>Survivors to receive education plus:
Vitamin D and Calcium Citrate: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6 months) Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day through study period (total treatment period approximately 6 months)</description>
        </group>
        <group group_id="B5">
          <title>Survivorship Standard of Care (Group B)</title>
          <description>Survivors either randomized to received standard of care with education alone OR vitamin D sufficient and continued for follow-up only.</description>
        </group>
        <group group_id="B6">
          <title>Siblings (Group C)</title>
          <description>Healthy siblings of subjects in Group A</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="B2" value="15" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="B3" value="14" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="B4" value="19" lower_limit="16" upper_limit="21"/>
                    <measurement group_id="B5" value="18" lower_limit="15" upper_limit="23"/>
                    <measurement group_id="B6" value="15" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="B7" value="15" lower_limit="10" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Vitamin D Level (Group A)</title>
        <description>Change in Vitamin D levels from baseline to study end (Group A: Consolidation through end of Delayed Intensification)</description>
        <time_frame>+6 months</time_frame>
        <population>Includes subjects in each group evaluable for vitamin D endpoint. Calculation of change = Vitamin D level at study end (end of DI, ~+6 months)/Vitamin D level at baseline (start of consolidation).</population>
        <group_list>
          <group group_id="O1">
            <title>On-Therapy Intervention (Group A)</title>
            <description>Subjects randomized following Induction to receive education plus:
Vitamin D and Calcium Citrate: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months) Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day through study period (total treatment period approximately 6-7 months)P</description>
          </group>
          <group group_id="O2">
            <title>On Therapy Standard of Care (Group A)</title>
            <description>Subjects randomized following Induction to receive standard of care with education alone OR subjects ineligible for open-label randomization and followed as &quot;natural history&quot; cohort.</description>
          </group>
          <group group_id="O3">
            <title>On-Therapy &quot;Natural History&quot; (Group A)</title>
            <description>Patients enrolled prior to open-label randomization and those not eligible for randomization at end of induction</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Vitamin D Level (Group A)</title>
          <description>Change in Vitamin D levels from baseline to study end (Group A: Consolidation through end of Delayed Intensification)</description>
          <population>Includes subjects in each group evaluable for vitamin D endpoint. Calculation of change = Vitamin D level at study end (end of DI, ~+6 months)/Vitamin D level at baseline (start of consolidation).</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in serum Vitamin 25(OH)D level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="1.7"/>
                    <measurement group_id="O2" value="-0.30" spread="2.2"/>
                    <measurement group_id="O3" value="1.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention serum Vitamin 25(OH)D level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="12.4"/>
                    <measurement group_id="O2" value="19.0" spread="7.4"/>
                    <measurement group_id="O3" value="23.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density by Quantitative Computed Tomography (QCT) at Study End (Group A)</title>
        <description>Bone mineral density (vBMD) at end of study period (Group A: end of Delayed Intensification)</description>
        <time_frame>+6 months</time_frame>
        <population>Subjects enrolled following the change to the open-label randomization were imaged for cortical bone density at the femur, subjects enrolled prior to this in the Natural History group were imaged at the tibia. The change was made for later subjects due to technical reasons to provide a better estimate of cortical density.</population>
        <group_list>
          <group group_id="O1">
            <title>On-Therapy Intervention (Group A)</title>
            <description>Subjects randomized following Induction to receive education plus:
Vitamin D and Calcium Citrate: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months) Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day through study period (total treatment period approximately 6-7 months)P</description>
          </group>
          <group group_id="O2">
            <title>On Therapy Standard of Care (Group A)</title>
            <description>Subjects randomized following Induction to receive standard of care with education alone OR subjects ineligible for open-label randomization and followed as &quot;natural history&quot; cohort.</description>
          </group>
          <group group_id="O3">
            <title>On-Therapy &quot;Natural History&quot; (Group A, Tibia)</title>
            <description>Patients enrolled prior to open-label randomization and those not eligible for randomization at end of induction</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density by Quantitative Computed Tomography (QCT) at Study End (Group A)</title>
          <description>Bone mineral density (vBMD) at end of study period (Group A: end of Delayed Intensification)</description>
          <population>Subjects enrolled following the change to the open-label randomization were imaged for cortical bone density at the femur, subjects enrolled prior to this in the Natural History group were imaged at the tibia. The change was made for later subjects due to technical reasons to provide a better estimate of cortical density.</population>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cortical BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2093.1" spread="62.5"/>
                    <measurement group_id="O2" value="2090.9" spread="26.7"/>
                    <measurement group_id="O3" value="927.5" spread="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancellous BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.8" spread="77.1"/>
                    <measurement group_id="O2" value="201.4" spread="66.4"/>
                    <measurement group_id="O3" value="159.1" spread="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vitamin D Level (Group B)</title>
        <description>Change in serum vitamin D level was assessed in survivors at baseline and after 6 months of supplementation</description>
        <time_frame>+6 months</time_frame>
        <population>Change in Vitamin D = Vitamin D at +6months/Vitamin D at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Survivorship Intervention (Group B)</title>
            <description>Subjects randomized to receive education plus directly-observed therapy with open-label Vitamin D and chewable calcium</description>
          </group>
          <group group_id="O2">
            <title>Survivorship Standard of Care (Group B)</title>
            <description>Survivors randomized to receive standard of care with education alone OR subjects ineligible for open-label Vitamin D+ Calcium randomization and continued with follow-up only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vitamin D Level (Group B)</title>
          <description>Change in serum vitamin D level was assessed in survivors at baseline and after 6 months of supplementation</description>
          <population>Change in Vitamin D = Vitamin D at +6months/Vitamin D at baseline</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in serum Vitamin 25(OH)D level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.2"/>
                    <measurement group_id="O2" value="-1.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention serum Vitamin 25(OH)D level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="2.0"/>
                    <measurement group_id="O2" value="29.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density by QCT in Survivors at Study End (Group B)</title>
        <description>Bone mineral density (vBMD) at end of study period (Group B: after 6 months)</description>
        <time_frame>+6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Survivorship Intervention (Group B)</title>
            <description>Subjects randomized to receive education plus directly-observed therapy with open-label Vitamin D and chewable calcium</description>
          </group>
          <group group_id="O2">
            <title>Survivorship Standard of Care (Group B)</title>
            <description>Survivors randomized to receive standard of care with education alone OR subjects ineligible for open-label Vitamin D+ Calcium randomization and continued with follow-up only.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density by QCT in Survivors at Study End (Group B)</title>
          <description>Bone mineral density (vBMD) at end of study period (Group B: after 6 months)</description>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cortical bone mineral density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2087.4" spread="39.3"/>
                    <measurement group_id="O2" value="2049.3" spread="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancellous bone mineral density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.6" spread="28.7"/>
                    <measurement group_id="O2" value="269.3" spread="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Obesity and Vitamin D Insufficiency in Adolescents With Newly Diagnosed ALL and in Their Siblings</title>
        <description>Insufficiency defined as 25(OH)D &lt; 30 ng/ml</description>
        <time_frame>1 timepoint</time_frame>
        <population>Group C: Only four siblings enrolled and arm closed early due to poor accrual. Specimens from this group were not analyzed so no results are available.
Group A: 39 subjects enrolled at diagnosis had Vitamin D testing performed at diagnosis and had results available.</population>
        <group_list>
          <group group_id="O1">
            <title>Siblings of Survivors (Group C)</title>
            <description>Healthy siblings of survivors of pediatric ALL for one-time assessment</description>
          </group>
          <group group_id="O2">
            <title>Newly Diagnosed Patients (Group A)</title>
            <description>Siblings enrolled in trial (Group A)</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Obesity and Vitamin D Insufficiency in Adolescents With Newly Diagnosed ALL and in Their Siblings</title>
          <description>Insufficiency defined as 25(OH)D &lt; 30 ng/ml</description>
          <population>Group C: Only four siblings enrolled and arm closed early due to poor accrual. Specimens from this group were not analyzed so no results are available.
Group A: 39 subjects enrolled at diagnosis had Vitamin D testing performed at diagnosis and had results available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months (Randomization to end of study)</time_frame>
      <desc>Note that subjects in the On-Therapy &quot;natural history&quot; arm (i.e. Group A, not randomized) were not formally followed for adverse event reporting.
Subjects in Sibling group (Arm C) had a single visit for a laboratory draw with no adverse event reporting indicated.</desc>
      <group_list>
        <group group_id="E1">
          <title>On Therapy Intervention (Group A)</title>
          <description>Subjects randomized following Induction to receive education plus:
Vitamin D and Calcium Citrate: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6 months) Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day through study period (total treatment period approximately 6 months)</description>
        </group>
        <group group_id="E2">
          <title>On Therapy Standard of Care (Group A)</title>
          <description>Subjects randomized following Induction to receive standard of care with education alone</description>
        </group>
        <group group_id="E3">
          <title>Survivorship Intervention (Group B)</title>
          <description>Survivors randomized to receive directly-observed therapy with open-label Vitamin and chewable calcium</description>
        </group>
        <group group_id="E4">
          <title>Survivorship Standard of Care (Group B)</title>
          <description>Survivors randomized to receive standard of care with education alone OR ineligible for open-label Vitamin D+Calcium randomization</description>
        </group>
        <group group_id="E5">
          <title>Siblings of Group A (Group C)</title>
          <description>Singling of Group A were enrolled for a one-time visit for labs; All-Cause Mortality, Serious, and Other [Not Including Serious] Adverse Events were not monitored/assessed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Etan Orgel</name_or_title>
      <organization>Children's Hospital Los Angeles</organization>
      <phone>3233612672</phone>
      <email>eorgel@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

